Evicenter
MarkdownMedical informationP&T meetings
Ifezuntirgene inilparvovec (AMT-130)

Huntington's disease

Manufacturer
uniQure
Launch
Not announced
Last updated
291 sources

Product information and disease descriptionPlace of product in therapyApproaches to treatment

Heterogeneity of treatment effect

11 evidence topics · 12 sources

Summary
  • Dose: the sponsor reports a difference between doses at 48 months in two statements. The third quarter 2026 release states that high-dose patients showed 1.1 points less decline on cUHDRS and 0.33 points less decline on TFC than low-dose patients. The four-year data release reports mean changes from baseline of –0.91 (high dose) and −1.94 (low dose) on cUHDRS, a difference of 1.03, and −0.30 and −0.70 on TFC, a difference of 0.40.
  • Striatal volume: in natural history data presented with the AMT-130 analyses, baseline striatal volume predicted clinical progression in TRACK-HD and predicted cUHDRS decline in the absence of other covariates, and was no longer predictive of cUHDRS or TFC decline when propensity score adjustments were applied. A fourth cohort of six participants with lower striatal volumes than participants in previous cohorts received high-dose AMT-130, with dosing completed in the fourth quarter of 2025.
  • Planned analyses: ICER's research protocol plans, data permitting, to evaluate treatment effect modification by HD stage (HD-ISS stages 2 and 3), concomitant antidopaminergic medication, and striatal volume. ICER's model analysis plan states that no heterogeneity and subgroup analyses are planned because currently available trial data are insufficient to support them. A public comment from Prilenia identified concomitant antidopaminergic medications as a pharmacologically important covariate that a chance imbalance in small studies can shift.
  • Natural history: in a progression model, TFC progression in individuals with HD-ISS 2 is not expected to differ from that in HD-ISS 3, and progression rates correlate weakly between clinical scores. In 960 participants, longer disease duration and better cognitive status at baseline were associated with less rapid TFC decline.
  • Other HD therapies: exploratory GENERATION HD1 analyses suggested benefit in younger participants with lower disease burden, but in GENERATION HD2 the biomarker effects did not translate into a meaningful clinical improvement. For pridopidine, post hoc analyses suggested benefit in participants not receiving antidopaminergic medications, and the European Medicines Agency noted that the validity and relevance of the subgroup results had not been demonstrated.